

Special Issue

Neurofibromatosis

Message from the Guest Editors

Neurofibromatosis type 1 (NF1), NF2-related schwannomatosis (NF2), and non-NF2-related schwannomatosis (SWN) are rare genetic disorders predisposing to the development of various tumors of the central and peripheral nervous systems. Although often benign, these neoplasms can still cause significant morbidity due to their size and/or location and are rarely amenable to surgical resection. It is therefore essential to translate pre-clinical advances into more effective treatment options for many of these tumors. To position these treatments, it is essential to understand the natural course, disease modifiers, and biomarkers. Finally, we are in need of a wider consensus on the preferred main outcomes of these potential treatments, including neurologic morbidity, vision, and ultimately, daily functioning and quality of life. In this Special Issue, we welcome original research articles and comprehensive review articles focusing on the disease course, disease modifiers, and treatments of tumors in patients with neurofibromatosis type 1, NF2-related schwannomatosis, and non-NF2-related schwannomatosis, aiming for significant advancements in this challenging yet fascinating field.

Guest Editors

Dr. Rianne Oostenbrink

Dr. Ignacio Blanco

Dr. Enrico Opocher

Deadline for manuscript submissions

closed (31 October 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/193550

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)